Tribute Pharmaceuticals Canada Inc (SLRXF) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
544 EGERTON ST LONDON, ON N5W 3Z8 |
| State of Incorp. | ON |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 2,813 | 2,284 | |||
| Cash and cash equivalents | 2,813 | 2,284 | |||
| Receivables | 592 | 1,205 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,045 | 1,001 | |||
| Inventory | 1,045 | 1,001 | |||
| Prepaid expense | 141 | ✕ | |||
| Deferred costs | 91 | ||||
| Prepaid expense and other current assets | ✕ | ✕ | 119 | ||
| Other undisclosed current assets | 693 | 277 | |||
| Total current assets: | 5,375 | 4,886 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 1,090 | 1,159 | |||
| Intangible assets, net (including goodwill) | 13,316 | 14,482 | |||
| Goodwill | 3,599 | 3,599 | |||
| Intangible assets, net (excluding goodwill) | 9,717 | 10,883 | |||
| Other undisclosed noncurrent assets | 254 | 301 | |||
| Total noncurrent assets: | 14,660 | 15,943 | |||
| TOTAL ASSETS: | 20,035 | 20,829 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 3,285 | 5,456 | |||
| Other undisclosed accounts payable and accrued liabilities | 3,285 | 5,456 | |||
| Debt | 205 | 1,306 | |||
| Derivative instruments and hedges, liabilities | 2,967 | 202 | |||
| Other undisclosed current liabilities | 38 | (202) | |||
| Total current liabilities: | 6,494 | 6,762 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 5,640 | 1,816 | |||
| Long-term debt, excluding current maturities | 5,640 | 1,816 | |||
| Liabilities, other than long-term debt | 315 | ||||
| Deferred tax liabilities, net | 315 | ||||
| Other undisclosed noncurrent liabilities | 202 | ||||
| Total noncurrent liabilities: | 5,640 | 2,333 | |||
| Total liabilities: | 12,134 | 9,094 | |||
| Equity | |||||
| Equity, attributable to parent | 7,900 | 11,734 | |||
| Common stock | 19,947 | 17,590 | |||
| Additional paid in capital | 2,287 | 1,868 | |||
| Accumulated other comprehensive loss | (38) | ||||
| Accumulated deficit | (14,296) | (7,724) | |||
| Warrants and rights outstanding | |||||
| Total equity: | 7,900 | 11,734 | |||
| TOTAL LIABILITIES AND EQUITY: | 20,035 | 20,829 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Revenues | 13,440 | 12,343 | ||
| Revenue, net | 13,836 | 12,343 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (1,542) | (1,221) | ||
| Other undisclosed gross profit | (5,901) | (5,953) | ||
| Gross profit: | 5,997 | 5,169 | ||
| Operating expenses | (11,076) | (9,590) | ||
| Operating loss: | (5,079) | (4,421) | ||
| Nonoperating income (expense) (Investment Income, Nonoperating) | (399) | 247 | ||
| Interest and debt expense | (527) | (147) | ||
| Loss from continuing operations: | (6,005) | (4,320) | ||
| Loss before gain (loss) on sale of properties: | (6,005) | (4,320) | ||
| Net loss: | (6,005) | (4,320) | ||
| Other undisclosed net income (loss) attributable to parent | (567) | 971 | ||
| Net loss available to common stockholders, diluted: | (6,572) | (3,349) | ||
Comprehensive Income ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Net loss: | (6,005) | (4,320) | ||
| Comprehensive loss: | (6,005) | (4,320) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (567) | 971 | ||
| Comprehensive loss, net of tax, attributable to parent: | (6,572) | (3,349) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.